Targeting the akt kinase to modulate survival, invasiveness and drug resistance of cancer cells

Current Medicinal Chemistry

Volumn 20, Issue 15, 2013, Pages 1923-1945

  Cassinelli, Giuliana ^a   Zuco, Valentina ^a   Gatti, Laura ^a   Lanzi, Cinzia ^a   Zaffaroni, Nadia ^a   Colombo, Diego ^b   Perego, Paola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Akt; Akt inhibitors; Angiogenesis; Drug resistance; Invasion

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; A 443654; ANTINEOPLASTIC AGENT; AZD 5363; BUPARLISIB; BZ 235; CAMPTOTHECIN; CARBOPLATIN; CETUXIMAB; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GCD 0941; GDC 0068; GEFITINIB; GSK 2141795; GSK 795; LAPATINIB; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; NAVELBINE; PACLITAXEL; PERIFOSINE; PERTUZUMAB; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; TAMOXIFEN; TRASTUZUMAB; TRICIRIBINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL FATE; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; DNA DAMAGE; DRUG MECHANISM; HUMAN; METASTASIS; NONHUMAN; PROTEIN TARGETING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84877936512     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990106     Document Type: Article

References (260)

1. Hers, I.; Vincent E.E.; Tavar J.M. Akt signaling in health and disease. Cell. Signal., 2011, 23, 1515-1527.
2. Franke T.F. PI3K/Akt: Getting it right matters. Oncogene, 2008, 27, 6473-6488.
3. Brunet, A.; Datta, S.R.; Greenberg, M.E. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol., 2001, 11, 297-305. (Pubitemid 32524094)
4. Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 1997, 91, 231-241. (Pubitemid 27456390)
5. Larue, L.; Bellacosa, A. Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene, 2005, 24, 7443-7454. (Pubitemid 41637984)
6. Jiang, B.H.; Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv. Cancer Res., 2009, 102, 19-25.
7. Grant, S. Cotargeting survival signalling pathways in cancer. J. Clin. Invest., 2008, 118, 3003-3006.
8. Gonzalez, E.; McGraw, T.E. The Akt kinases: Isoform specificity in metabolism and cancer. Cell Cycle, 2009, 8, 2502-2508.
9. Kumar, C.C.; Madison, V. AKT crystal structure and AKT-specific inhibitors. Oncogene, 2005, 24, 7493-7501. (Pubitemid 41637989)
10. Stambolic, V.; Woodgett, J.R. Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol., 2006, 16, 461-466. (Pubitemid 44293397)
11. Heron-Milhavet, L.; Khouya, N.; Fernandez, A.; Lamb, N.J. Akt1 and Akt2: Differentiating the aktion. Histol. Histopathol., 2011, 26, 651-662.
12. Cho, H.; Mu, J., Kim, J.K.; Thorvaldsen, J.L.; Chu, Q.; Crenshaw, E.B. III; Kaestner, K.H.; Bartolomei, M.S.; Shulman, G.I.; Birnbaum, M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science, 2001; 292, 1728-1731. (Pubitemid 32506248)
13. Cho, H.; Thorvaldsen, J.L.; Chu, Q.; Feng, F.; Birnbaum, M.J. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem., 2001, 276, 38349-38352.
14. Chin, Y.R.; Toker, A. Akt isoform-specific signaling in breast cancer: Uncovering an anti-migratory role for palladin. Cell Adhesion Migration, 2011, 5, 211-214.
15. Chin, Y.R.; Toker, A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal, 2009, 21, 470-476.
16. Manning, B.D.; Cantley, L.C. AKT/PKB signaling: Navigating downstream. Cell, 2007, 129, 1261-1274. (Pubitemid 46962095)
17. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307, 1098-1101. (Pubitemid 40262113)
18. Mahajan, K.; Mahajan, N.P. PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics. J. Cell. Physiol., 2012, 227, 3178-3184.
19. Carpten, J.D.; Faber, A.L., Horn, C.; Donoho, G.P.; Briggs, S.L.; Robbins, C.M.; Hostetter G.; Boguslawski, S.; Moses, T.Y.; Savage, S.; Uhlik, M.; Lin, A.; Du, J.; Qian, Y.W.; Zeckner, D.J.; Tucker-Kellogg, G.; Touchman, J.; Patel, K.; Mousses, S.; Bittner, M.; Schevitz, R.; Lai, M.H.; Blanchard, K.L.; Thomas, J.E. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature, 2007, 448, 439-444. (Pubitemid 47123510)
20. Bleeker, F.E.; Felicioni, L.; Buttitta, F.; Lamba, S.; Cardone, L.; Rodolfo M.; Scarpa, A.; Leenstra, S.; Frattini, M.; Barbareschi, M.; Grammastro, M.D.; Sciarrotta, M.G.; Zanon, C.; Marchetti, A.; Bardelli, A. AKT1(E17K) in human solid tumours. Oncogene, 2008, 27, 5648-5650.
21. Ricarte-Filho, J.C.; Ryder, M.; Chitale, D.A.; Rivera, M.; Heguy, A.; Ladanyi, M.; Janakiraman, M.; Solit, D.; Knauf, J.A.; Tuttle, R.M.; Ghossein, R.A.; Fagin, J.A. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res., 2009, 69, 4885-4893.
22. Banerji, S.; Cibulskis, K.; Rangel-Escareno, C.; Brown, K.K.; Carter, S.L.; Frederick, A.M; Lawrence, M.S; Sivachenko, A.Y; Sougnez, C.; Zou, L.; Cortes, M.L.; Fernandez-Lopez, J.C.; Peng, S.; Ardlie, K.G.; Auclair, D.; Bautista-Pi, V.; Duke, F.; Francis, J.; Jung, J.; Maffuz-Aziz, A.; Onofrio, R.C.; Parkin, M.; Pho, N.H.; Quintanar-Jurado, V.; Ramos, A.H.; Rebollar-Vega, R.; Rodriguez-Cuevas, S.; Romero-Cordoba, S.L.; Schumacher, S.E.; Stransky, N.; Thompson, K.M.; Uribe-Figueroa, L.; Baselga, J.; Beroukhim, R.; Polyak, K.; Sgroi, D.C.; Richardson, A.L.; Jimenez-Sanchez, G.; Lander, E.S.; Gabriel, S.B.; Garraway, L.A.; Golub, T.R.; Melendez-Zajgla, J.; Toker, A.; Getz, G.; Hidalgo-Miranda, A.; Meyerson, M. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 2012, 486, 405-409.
23. Martelli, A.M.; Tabellini, G.; Bressanin, D.; Ognibene, A.; Goto, K.; Cocco, L.; Evangelisti, C.; The emerging multiple roles of nuclear Akt. Biochim. Biophys. Acta, 2012, 1823, 2168-2178.
24. Pestell, R.G.; Albanese, C.; Reutens, A.T.; Segall, J.E.; Lee, R.J.; Arnold, A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr. Rev., 1999, 20, 501-534. (Pubitemid 30647078)
25. Zhou, B.P.; Liao, Y.; Xia, W.; Spohn, B.; Lee, M.H.; Hung, M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell. Biol., 2001, 3, 245-252. (Pubitemid 32201319)
26. Li, Y.; Dowbenko, D.; Lasky, L.A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J. Biol. Chem., 2002, 277, 11352-11361. (Pubitemid 34952901)
27. Medema, R.H.; Kops, G.J.; Bos, J.L.: Burgering, B.M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27(kip1). Nature, 2000, 404, 782-787. (Pubitemid 30212408)
28. Diehl, J.A.; Cheng, M.; Roussel, M.F.; Sherr, C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 1998, 12, 3499-3511. (Pubitemid 28553242)
29. Gregory, M.A.; Qi, Y.; Hann, S.R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem., 2003, 278, 51606-51612. (Pubitemid 38020405)
30. Feng, J.; Tamaskovic, R.; Yang, Z.; Brazil, D.P.; Merlo, A.; Hess, D.; Hemmings, B.A. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J. Biol. Chem., 2004, 279, 35510-35517. (Pubitemid 39100551)
31. Maddika, S.; Sande, S.R.; Wiechec, E.; Hansen, L.L.; Wesselborg, S.; Los, M. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J. Cell. Sci., 2008, 121, 979-988. (Pubitemid 351639417)
32. Katayama, K.; Fujita, N.; Tsuruo, T. Akt/protein kinase Bdependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol. Cell. Biol., 2005, 25, 5725-5737. (Pubitemid 40853605)
33. Okumura, E.; Fukuhara, T.; Yoshida, H.; Hanada Si, S.; Kozutsumi, R.; Mori, M.; Tachibana, K.; Kishimoto, T. Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition. Nat. Cell. Biol., 2002, 4, 111-116. (Pubitemid 34141476)
34. Baldin, V.; Theis-Febvre, N; Benne, C.; Froment, C.; Cazales, M.; Burlet-Schiltz, O.; Ducommun, B. PKB/Akt phosphorylates the CDC25B phosphatase and regulates its intracellular localisation. Biol. Cell., 2003, 95, 547-554. (Pubitemid 37461485)
35. Héon-Milhavet, L.; Franckhauser, C.; Rana, V.;, Berthenet, C.; Fisher, D.; Hemmings, B.A.; Fernandez, A.; Lamb, N.J. Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol. Cell. Biol., 2006, 26, 8267-8280. (Pubitemid 44748563)
36. Brazil, D.P.; Yang, Z.Z.; Hemmings, B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci., 2004, 29, 233-242. (Pubitemid 38591317)
37. Koseoglu, S.; Lu, Z.; Kumar, C.; Kirschmeier, P.; Zou, J. AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines. Can. Biol. Ther., 2007, 6, 755-762. (Pubitemid 47328358)
38. Mure, H.; Matsuzaki, K.; Kitazato, K.T.; Mizobuchi, Y.; Kuwayama, K.; Kageji, T.; Nagahiro, S. Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol., 2010, 12, 221-232.
39. Liang, J.; Slingerland, J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle, 2003, 2, 339-345.
40. Rosner, M.; Freilinger, A.; Hengstschläer, M. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27. Mutat. Res., 2006, 613, 10-16. (Pubitemid 44382645)
41. Xu, P.Z.; Chen, M.L.; Jeon, S.M.; Peng, X.D.; Hay, N. The effect Akt2 deletion on tumor development in Pten(+/-) mice. Oncogene, 2012, 31, 518-526.
42. Bozulic, L.; Surucu, B.; Hynx, D.; Hemmings, B.A. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol. Cell., 2008, 30, 203-213. (Pubitemid 351626686)
43. Stracker, T.H.; Petrini, J.H. The MRE11 complex: Starting from the ends. Nat. Rev. Mol. Cell. Biol., 2011, 12, 90-103
44. Fraser, M.; Harding, S.M.; Zhao, H.; Coackley, C,.; Durocher, D.; Bristow, R.G. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle, 2011, 10, 2218-2232.
45. Guinea Viniegra, J.; Martíez, N.; Modirassari, P.; Hernádez Losa , J.; Parada Cobo, C.; Sáchez-Arévalo Lobo, V.J.; Aceves Luquero, C.I.; Alvarez-Vallina, L; Ramyon y Cajal, S.; Rojas, J.M.; Sáchez-Prieto, R. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J. Biol. Chem., 2005, 280, 4029-4036. (Pubitemid 40288566)
46. Boehme, K.A.; Kulikov, R.; Blattner, C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc. Nat. Acad. Sci. USA, 2008, 105, 7785-7790. (Pubitemid 351872716)
47. Toulany, M.; Kasten-Pisula, U.; Brammer, I.; Wang, S.; Chen, J.; Dittmann, K.; Baumann, M.; Dikomey, E.; Rodemann, H.P. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin. Cancer Res., 2006, 12, 4119-4126. (Pubitemid 44078101)
48. Toulany, M.; Kehlbach, R.; Florczak, U.; Sak, A.; Wang, S.; Chen, J.; Lobrich, M.; Rodemann, H.P. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcsdependent DNA double-strand break repair. Mol. Cancer Ther., 2008, 7, 1772-1781.
49. Golding, S.E.; Morgan, R.N.; Adams, B.R.; Hawkins, A.J.; Povirk, L.F.; Valerie, K. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol. Ther., 2009, 8, 730-738.
50. Tonic, I.; Yu, W.N.; Park, Y.; Chen, C.C.; Hay, N. Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci. J. Biol. Chem., 2010, 285, 23790-23798.
51. Plo, I.; Laulier, C.; Gauthier, L.; Lebrun, F.; Calvo, F.; Lopez, B.S. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res., 2008, 68, 9404-9412.
52. Xiang, T.; Ohashi, A.; Huang, Y.; Pandita, T.K.; Ludwig, T.; Powell, S.N.; Yang, Q. Negative Regulation of AKT Activation by BRCA1. Cancer Res., 2008, 68, 10040-10044.
53. Jia, Y.; Song, W.; Zhang, F.; Yan, J.; Yang Q. Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway. Oncogene, 2012, doi: 10.1038/onc.2012.211.
54. Zanchi, C.; Zuco, V.; Lanzi, C.; Supino, R.; Zunino F. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. Cancer Res., 2005, 65, 2364-2372. (Pubitemid 40490147)
55. Del Peso, L.; Gonzaez-Garcia, M.; Page, C.; Herrera, R.; Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science, 1997, 278, 687-689. (Pubitemid 27464966)
56. Datta, S.R.; Ranger, A.M.; Lin, M.Z.; Sturgill, J.F.; Ma, Y.C.; Cowan. C.W; Dikkes, P.; Korsmeyer, S.J.; Greenberg, M.E. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev. Cell., 2002, 3, 631-643. (Pubitemid 35339482)
57. Maddika, S.; Ande, S.R.; Panigrahi, S.; Paranjothy, T.; Weglarczyk, K.; Zuse, A.; Eshraghi, M.; Manda, K.D.; Wiechec, E.; Los, M. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist. Updat., 2007, 10, 13-29. (Pubitemid 46636381)
58. Kim, A.H.; Khursigara, G.; Sun, X.; Franke, T.F.; Chao, M.V. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell. Biol., 2001, 21, 893-901. (Pubitemid 32104737)
59. Cardone, M.H.; Roy, N.; Stennicke, H.R.; Salvesen, G.S.; Franke, T.F.; Stanbridge, E.; Frisch, S.; Reed, J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science, 1998, 282, 1318-1321. (Pubitemid 28524494)
60. Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 1999, 96, 857-868. (Pubitemid 29165088)
61. Romashkova, J.A.; Makarov, S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 1999, 401, 86-90.
62. Nicholson, K.M.; Anderson, N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal., 2002, 14, 381-395. (Pubitemid 34214843)
63. Wang, J.M.; Chao, J.R.; Chen, W.; Kuo, M.L.; Yen, J.J.; Yang-Yen, H.F.The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol., 1999, 19, 6195-6206. (Pubitemid 29399324)
64. Ouyang, L.; Shi, Z.; Zhao, S.; Wang, F.T.; Zhou, T.T.; Liu, B.; Bao, J.K. Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell. Prolif., 2012, 45, 487-498.
65. Populo, H.; Lopes, J.M.; Soares, P. The mTOR signaling pathway in human cancer. Int. J. Mol. Sci., 2012, 13, 1886-1918.
66. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell. Biol., 2002, 4, 648-657. (Pubitemid 34993700)
67. Degtyarev, M.; De Mazie, A.; Orr, C.; Lin, J.; Lee, B.B.; Tien, J.Y.; Prior, W.W.; van Dijk, S.; Wu, H.; Gray, D.C.; Davis, D.P.; Stern, H.M.; Murray, L.J.; Hoeflich, K.P.; Klumperman, J.; Friedman, L.S.; Lin, K. Akt inhibition promotes autophagy and sensi tizes PTEN-null tumors to lysosomotropic agents. J. Cell Biol., 2008, 183, 101-116.
68. Santi, S.A.; Lee, H. Ablation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells. PLoS One, 2011, 6, e14614.
69. Zhou, J.; Liao, W.; Yang, J.; Ma, K.; Li, X.; Wang, Y.; Wang, D.; Wang, L.; Zhang, Y.; Yin, Y.; Zhao, Y.; Zhu, W.G. FOXO3 induces FOXO1-dependent autophagy by activating the AKT1 signaling pathway. Autophagy, 2012, 8, 1712-1723.
70. Appenzeller-Herzog, C.; Hall, M.N. Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cel.l Biol., 2012, 5, 274-282.
71. Nogueira, V.; Park, Y.; Chen, C.C.; Xu, P.Z.; Chen M.L.; Tonic, L.; Unterman, T.; Hay, N. Akt determined replicative senescence and oxidative stress or oncogenic premature senescence and sensitizies cells to oxidative apoptosis. Cancer Cell, 2008, 14, 458-470.
72. Minamino, T.; Miyauchi, H.; Tateno, K.; Kunieda, T.; Komuro, I. Akt-induced cellular senescence: Implication for human disease. Cell Cycle, 2004, 3, 449-451. (Pubitemid 40278235)
73. Braig, M.; Schmitt, C.A. Oncogene-induced senescence: Putting the brakes on tumor development. Cancer Res. 2006, 66, 2881-2884.
74. Ohgaki, H.; Dessen, P.; Jourde, B.; Horstmann, S.; Nishikawa, T.; Di Patre, P.L.; Burkhard, C.; Scher, D.; Probst-Hensch, N.M.; Maiorka, P.C.; Baeza, N.; Pisani, P.; Yonekawa, Y.; Yasargil, M.G.; Lolf, U.M.; Kleihues, P. Genetic pathways to glioblastoma: A population-based study. Cancer Res., 2004, 64, 6892-6899. (Pubitemid 39330996)
75. Lee, J.J.; Kim, B.C.; Park, M.J.; Lee, Y.S.; Kim, Y.N.; Lee, B.L.; Lee, J.S. PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ., 2011, 18, 666-677.
76. Miyauchi, H.; Minamino, T.; Tateno, K.; Kunieda, T.; Toko, H.; Komuro, I. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J., 2004, 23, 212-220. (Pubitemid 38165761)
77. Sun, Y.; St. Clair, D.K.; Xu, Y.; Crooks, P.A.; St. Clair, W.H. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res., 2010, 70, 2880-2890.
78. Nosho, K.; Kawasaki, T; Ohnishi, M.; Suemoto, Y.; Kirkner, G.J.; Zepf, D.; Yan, L.; Longtine, J.A.; Fuchs, C.S.; Ogino, S. PIK3CA mutation in colorectal cancer: Relationship with genetic and epigenetic alterations. Neoplasia, 2008, 10, 534-541. (Pubitemid 351770297)
79. Andjelkovic, T.; Bankovic, J.; Stojsic, J.;, Milinkovic, V.; Podolski-Renic, A.; Ruzdijic S.; Tanic N. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl. Res., 2011, 157, 19-28.
80. Puzio-Kuter, A.M.; Castillo-Martin, M.; Kinkade, C.W.; Wang, X.; Shen, T.H.; Matos, T.; Shen, M.M.; Cordon-Cardo, C.; Abate-Shen, C. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev., 2009, 23, 675-680.
81. Samuels, Y.; Ericson, K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol., 2006, 18, 77-82. (Pubitemid 43740454)
82. Kolsch, V.; Charest, P.G.; Firtel, R.A. The regulation of cell motility and chemotaxis by phospholipid signaling. J. Cell Sci., 2008, 121, 551-559. (Pubitemid 351524153)
83. LoPiccolo, J.; Blumenthal, G,M.; Bernstein, W.B.; Dennis, P.A. Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist. Updat., 2008, 11, 32-50.
84. Meili, R.; Ellsworth, C.; Lee, S.; Reddy, T.B.; Ma, H.; Firtel, R.A. Chemoattractant-mediated transient activation and membrane localization of Akt/PKB is required for efficient chemotaxis to cAMP in Dictyostelium. EMBO J., 1999, 18, 2092-2105. (Pubitemid 29179167)
85. Servant, G.; Weiner, O.D.; Herzmark, P.; Balla, T.; Sedat, J.W.; Bourne, H.R. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science, 2000, 287, 1037-1040. (Pubitemid 30094359)
86. Tanno, S.; Mitsuuchi, Y.; Altomare, D.A.; Xiao, G.H.; Testa, J.R. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res., 2001, 61, 589-593. (Pubitemid 32128619)
87. Park, B.K.; Zeng, X.; Glazer, R.I. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res., 2001, 61, 7647-7653. (Pubitemid 32995061)
88. Chung, C.Y.; Funamoto, S.; Firtel, R.A. Signaling pathways controlling cell polarity and chemotaxis. Trends Biochem. Sci., 2001, 26, 557-566. (Pubitemid 32823441)
89. Vanhaesebroeck, B.; Guillermet-Guibert, J.; Graupera, M.; Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nature Rev., 2010, 11, 329-341.
90. Samuels, Y.; Diaz, L.A.; Schmidt-Kittler, O.; Cummins, J.M.; DeLong, L.; Cheong, I.; Rago, C.; Huso, D.L.; Lengauer, C.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 2005, 7, 561-573. (Pubitemid 40799249)
91. Song, M.S.; Salmena, L.; Pandolfi, P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell. Biol., 2012, 13, 283-296.
92. Tamura, M.; Gu, J.; Takino, T.; Yamada, K.M. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas. Cancer Res., 1999, 59, 442-449. (Pubitemid 29048881)
93. Zhang, S.; YU, D. PI(3)King apart PTEN's role in cancer. Clin. Cancer Res., 2010, 16, 4325-4330.
94. Ligresti, G.; Militello, L.; Steelman, L.S.; Cavallaro, A.; Basile, F.; Nicoletti, F.; Stivala, F.; McCubrey, J.A.; Libra, M. PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches. Cell Cycle, 2009, 8, 1352-1358.
95. Wu, G.; Mambo, E.; Guo, Z.; Hu, S.; Huang, X.; Gollin, S.M.; Trink, B.; Ladenson, P.W.; Sidransky, D.; Xing, M. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J. Clin. Endocrinol. Metab., 2005, 90, 4688-4693. (Pubitemid 41159359)
96. Saal, L.H.; Holm, K.; Maurer, M.; Memeo, L.; Su, T.; Wang, X.; Yu, J.S.; Malmstr, P.O.; Mansukhani, M.; Enoksson, J.; Hibshoosh, H.; Borg, A.; Parsons, R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res., 2005, 65, 2554-2559. (Pubitemid 40490050)
97. Wallin, J.J.; Guan, J.; Edgar, K.A.; Zhou, W.; Francis, R.; Torres, A.C.; Haverty, P.M.; Eastham-Anderson, J.; Arena, S.; Bardelli, A.; Griffin, S.; Goodall, J.E.; Grimshaw, K.M.; Hoeflich, K.P.; Torrance, C.; Belvin, M.; Friedman, L.S. Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. PLoS One, 2012, 7, e36402.
98. Morrow, C.J.; Gray, A.; Dive, C. Comparison of phosphatidylinositol-3- kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS Lett., 2005, 579, 5123-5128. (Pubitemid 41318079)
99. Pang, H.; Flinn, R.; Patsialou, A.; Wyckoff, J.; Roussos, E.T.; Wu, H.; Pozzuto, M.; Goswami, S.; Condeelis, J.S.; Bresnick, A.R.; Segall, J.E.; Backer, J.M. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res., 2009, 69, 8868-8876.
100. Kim, D.; Kim, S.; Koh, H.; Yoon, S.O.; Chung, A.S.; Cho, K.S.; Chung J. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J., 2001, 15, 1953-1962. (Pubitemid 32848799)
101. Kubiatowski, T.; Jang, T.; Lachyankar, M.B.; Salmonsen, R.; Nabi, R.R.; Quesenberry, P.J.; Litofsky, N.S.; Ross, A.H.; Recht, L.D. Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J. Neurosurg., 2001, 95, 480-488. (Pubitemid 32781501)
102. Furuya, F.; Lu, C.; Willingham, M.C.; Cheng, S. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis, 2007, 28, 2451-2458. (Pubitemid 350238946)
103. Wang, Y.; Hou, P.; Yu, H.; Wang, W.; Ji, M.; Zhao, S.; Yan, S.; Sun, X.; Liu, D.; Shi, B.; Zhu, G.; Condouris, S.; Xing, M. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J. Clin. Endocrinol. Metab., 2007, 92, 2387-2390. (Pubitemid 46997152)
104. Hou, P.; Liu, D.; Shan, Y.; Hu, S.; Studeman, K.; Condouris, S.; Wang, Y.; Trink, A.; El-Naggar, A.K.; Tallini, G.; Vasko, V.; Xing, M. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res., 2007, 13, 1161-1170. (Pubitemid 46424056)
105. Kim, C.S.; Vasko, V.V.; Kato, Y.; Kruhlak, M.; Saji, M.; Cheng, S.Y.; Ringel, M.D. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology, 2005, 146, 4456-4463. (Pubitemid 41324044)
106. Saji, M.; Narahara, K.; McCarty, S.K.; Vasko, V.V.; La Perle, K.M.; Porter, K.; Jarjoura, D.; Lu, C.; Cheng, S.Y.; Ringel, M.D. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene, 2011, 30, 4307-4315.
107. Vasko, V.; Saji, M.; Hardy, E.; Kruhlak, M.; Larin, A.; Savchenko, V.; Miyakawa, M.; Isozaki, O.; Murakami, H.; Tsushima, T.; Burman, K.D.; De Micco, C.; Ringel, M.D. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet., 2004, 41, 161-170. (Pubitemid 38333792)
108. Cassinelli, G.; Favini, E.; Degl'Innocenti, D.; Salvi, A.; De Petro, G.; Pierotti, M.A.; Zunino, F.; Borrello, M.G.; Lanzi, C. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia, 2009, 11, 10-21.
109. Liu, Z.; Hou, P.; Ji, M.; Guan, H.; Studeman, K.; Jensen, K.; Vasko, V.; El-Naggar, A.K.; Xing, M. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab., 2008, 93, 3106-3116.
110. Zhou, G.L.; Tucker, D.F.; Bae, S.S., Bhatheja, K.; Birnbaum, M.J.; Field, J. Opposing roles for Akt1 and Akt2 in Rac/Pak signaling and cell migration. J. Biol. Chem., 2006, 281, 36443-36453. (Pubitemid 46041378)
111. Huang, Q.; Sheibani, N. High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am. J. Physiol. Cell Physiol., 2008, 295, C1647-1657.
112. Arboleda, M.J.; Lyons, J.F.; Kabbinavar, F.F., Bray, M.R.; Snow, B.E.; Ayala, R.; Danino, M.; Karlan, B.Y.; Slamon, D.J. Overexpression of AKT2/protein kinase B? leads to up-regulation of ?1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res., 2003, 63, 196-206. (Pubitemid 36070440)
113. Nakayama, K.; Nakayama, N.; Kurman, R.J.; Cope, L.;, Pohl, G.; Samuels, Y.; Velculescu, V.E.; Wang, T.L.; Shih, IeM. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther., 2006, 5, 779-785. (Pubitemid 44775134)
114. Hollier, B.G.; Kricker, J.A.; Van Lonkhuyzen, D.R.; Leavesly, D.I.; Upton, Z. Substrate-bound insulin-like growth factor (UGF)-IIGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-kinase/AKT pathway by ?v-integrins and the IGF-I receptor. Endocrinology, 2008, 149, 1075-1090. (Pubitemid 351397938)
115. Ju, X.; Katiyar, S.; Wang, C.; Liu, M.; Jiao, X.; Li, S.; Zhou, J.; Turner, J.; Lisanti, M.P.; Russell, R.G.; Mueller, S.C.; Ojeifo, J.; Chen, W.S.; Hay, N.; Pestell, R.G. Akt1 governs breast cancer progression in vivo. Proc. Natl. Acad. Sci. USA, 2007, 104, 7438-7443. (Pubitemid 47185924)
116. Perez-Tenorio, G.; Stal, O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer, 2002, 86, 540-545. (Pubitemid 34185089)
117. Hutchinson, J.N.; Jin, J.; Cardiff, R.D.; Woodgett, J.R.; Muller, W.J. Activation of Akt-1 (PKB-α) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res., 2004, 64, 3171-3178. (Pubitemid 38581419)
118. Maroulakou, I.G.; Oemler, W.; Naber, S.P.; Tsichlis, P.N. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res., 2007, 67, 167-177. (Pubitemid 46142772)
119. Yoeli-Lerner, M.; Yiu, G.K.; Rabinovitz, I.; Erhardt, P.; Jauliac, S.; Toker, A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol. Cell., 2005, 20, 539-550. (Pubitemid 41668639)
120. Irie, H.Y.; Pearline, R.V.; Grueneberg, D.; Hsia, M.; Ravichandran, P.; Kothari, N.; Natesan, S.; Brugge, J.S. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell. Biol., 2005, 171, 1023-1034. (Pubitemid 41815834)
121. Ruggeri, B.A.; Huang, L.; Wood, M.; Cheng, J.Q.; Testa, J.R. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog., 1998, 21, 81-86. (Pubitemid 28122842)
122. Ericson, K.; Gan, C.; Cheong, I.; Rago, C.; Samuels, T.; Velculescu, V.E.; Kinzler, K.W.; Huso, D.L.; Vogelstein, B.; Papadopoulos, N. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. PNAS, 2010, 107, 2598-2603.
123. Lee, M.W.; Kim, D.S.; Lee, J.H.; Lee, B.S.; Lee, S.H.; Jung, H.L.; Sung, K.W.; Kim, H.T.; Yoo, K.H.; Koo, H.H. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Sci., 2011, 102, 1822-1828.
124. David, O.; Jett, J.; LeBeau, H.; Dy, G.; Hughes, J.; Friedman, M.; Brody, A.R. Phospho-Akt overexpression in Non-Small Cell Lung Cancer confers significant stage-independent survival disadvantage. Clin Cancer Res., 2004, 10, 6865-6871. (Pubitemid 39383035)
125. Dobashi, Y.; Kimura, M.; Matsubara, H.; Endo, S.; Inazawa, J.; Ooi, A. Molecular alterations in AKT and its protein activation in human lung carcinomas. Human Pathol., 2012, 43, 2229-2240.
126. Scrima, M.; De Marco, C.; Fabiani, F.; Franco, R.; Pirozzi, G.; Rocco, G.; Ravo, M.; Weisz, A.; Zoppoli, P.; Ceccarelli, M.; Botti, G.; Malanga, D.; Viglietto, G. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): New insights on the role of phosphatydil-inositol-3 kinase. PLoS One, 2012, 7, e30427.
127. Davies, M.A. The role of the PI3K-AKT pathway in melanoma. Cancer J., 2012, 18, 142-147.
128. Dankort, D.; Curley, D.P.; Cartlidge, R.A.; Nelson, B.; Karnezis, A.N.; Damsky, W.E. Jr,; You, M.J.; DePinho, R.A.; McMahon, M.; Bosenberg, M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet., 2009, 41, 544-552.
129. Nogueira, C.; Kim, K-H.; Sung, H.; Paraiso, K.; Dannenberg, J-H.; Bosenberg, M.; Chin, L.; Kim, M. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene, 2010, 29, 6222-6232.
130. Karar, J.; Maity, A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci., 2011, 4, 51.
131. Emerling, B.M.; Weinberg, F.; Liu, J.L.; Mak, T.W.; Chandel, N.S. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Fork-head transcription factor 3a (FOXO3a) Proc. Natl. Acad. Sci. USA, 2008, 105, 2622-2627. (Pubitemid 351520563)
132. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet., 2006, 7, 606-619. (Pubitemid 44100518)
133. Wang, F.S.; Kuo, Y.R.; Wang, C.J.; Yang, K.D.; Chang, P.R.; Huang, Y.T.; Huang, H.C.; Sun, Y.C.; Yang, Y.J.; Chen, Y.J. Nitric oxide mediates ultrasound-induced hypoxia-inducible factor-1alpha activation and vascular endothelial growth factor-A expression in human osteoblasts. Bone, 2004, 35, 114-123. (Pubitemid 38789154)
134. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol., 2010, 28, 1075-1083.
135. Yuan, T.L.; Choi, H.S.; Matsui, A.; Benes, C.; Lifshits, E.; Luo, J.; Frangioni, J.V.; Cantley, L.C. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc. Natl. Acad. Sci. USA., 2008, 105, 9739-9744 . (Pubitemid 352031370)
136. Graupera, M.; Guillermet-Guibert ,J.; Foukas, L.C.; Phng, L.K.;Cain, R.J.;Salpekar, A.;Pearce, W.; Meek, S.; Millan, J.; Cutillas, P.R.; Smith, A.J.; Ridley, A.J.; Ruhrberg, C.; Gerhardt, H.; Vanhaesebroeck, B. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature, 2008, 453, 662-666. (Pubitemid 351769296)
137. Suzuki, A.; Hamada, K.; Sasaki, T.; Mak, T.W.; Nakano, T. Role of PTEN/PI3K pathway in endothelial cells. Biochem. Soc. Trans., 2007, 35, 172-176. (Pubitemid 46596460)
138. Cebe-Suarez, S.; Zehnder-Fjallman, A.; Ballmer-Hofer, K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell. Mol. Life Sci., 2006, 63, 601-615.
139. Lin, J.; Lalani, A.S.; Harding, T.C.; Gonzalez, M.;Wu, W.W.; Luan, B.; Tu, G.H.; Koprivnikar, K.; VanRoey, M.J.; He, Y.; Alitalo, K.; Jooss, K. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res., 2005, 65, 6901-6909. (Pubitemid 41060729)
140. Makinen, T.; Jussila, L.; Veikkola, T.; Karpanen; T.; Kettunen, M.I.; Pulkkanen, K.J.; Kauppinen, R.; Jackson, D.G.; Kubo, H.; Nishikawa, S.; Yla-Herttuala, S.; Alitalo, K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med., 2001, 7, 199-205. (Pubitemid 32148487)
141. Shiojima, I.; Walsh, K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res., 2002, 90, 1243-1250. (Pubitemid 34787405)
142. Kim, I.; Kim, H.G.; So, J.N.; Kim, J.H.; Kwak, H.J.; Koh, G.Y. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3?-Kinase/Akt signal transduction pathway. Circ Res., 2000, 86, 24-29. (Pubitemid 30044164)
143. Babaei, S.; Teichert-Kuliszewska, K.; Zhang, Q.; Jones, N.; Dumont, D.J.; Stewart, D.J. Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am. J. Pathol., 2003, 162, 1927-1936. (Pubitemid 36613050)
144. Makinde, T.; Agrawal, D.K. Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. J. Cell. Mol. Med., 2008, 12, 810-828. (Pubitemid 351718065)
145. Miao, H.; Li, D.Q.; Mukherjee, A.; Guo, H.; Petty, A.; Cutter, J.; Basilion, J.P.; Sedor, J.; Wu, J.; Danielpour , D.; Sloan, A.E.; Cohen, M.L,.;Wang, B. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell, 2009, 16, 9-20.
146. Pitulescu, M.E.; Adams, R.H. Eph/ephrin molecules-A hub for signaling and endocytosis. Genes Dev., 2010, 24, 2480-2492.
147. Jiang, B.H.; Zheng, J.Z.; Aoki, M.; Vogt, P.K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. USA., 2000, 97, 1749-1753. (Pubitemid 30118514)
148. Lelievre, E.; Bourbon, P.M.; Duan, L.J.; Nussbaum, R.L.; Fong, G.H. Deficiency in the p110alpha subunit of PI3K results in diminished Tie2 expression and Tie2(?/?)-like vascular defects in mice. Blood, 2005, 105, 3935-3938. (Pubitemid 40656139)
149. Bader, A.G.; Kang. S.; Vogt, PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA., 2006, 103, 1475-1479. (Pubitemid 43191190)
150. Yang, Z.Z.; Tschopp, O.; Hemmings-Mieszczak ,M.; Feng, J.; Brodbeck, D.; Perentes, E.; Hemmings, B.A. Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J. Biol. Chem., 2003, 278, 32124-32131. (Pubitemid 37048402)
151. Chen, J.; Somanath, P.R.; Razorenova, O.; Chen, W.S.; Hay, N.; Bornstein, P.; Byzova, T.V. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat. Med., 2005, 11, 1188-1196. (Pubitemid 43093666)
152. Niu, Q.; Perruzzi, C.; Voskas, D.; Lawler, J.; Dumont, D.J.;, Benjamin, L.E. Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol. Ther., 2004, 3, 402-405. (Pubitemid 41350872)
153. Phung, T.L.; Ziv, K.; Dabydeen, D.; Eyiah-Mensah, G.; Riveros, M.; Perruzzi, C.; Sun J, Monahan-Earley, R.A.; Shiojima, I.; Nagy, J.A.; Lin, M.I.; Walsh, K.; Dvorak, A.M.; Briscoe, D.M.; Neeman, M.; Sessa, W.C.; Dvorak, H.F.; Benjamin, L.E. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006, 10, 159-170. (Pubitemid 44175906)
154. Nyberg, P.; Salo, T.; Kalluri, R. Tumor microenvironment and angiogenesis. Front Biosci,. 2008, 13, 6537-6553.
155. Skinner, H.D.; Zheng, J.Z.; Fang, J.; Agani, F.; Jiang, B.H. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J. Biol. Chem., 2004, 279, 45643-45651. (Pubitemid 39491552)
156. Wallace, J.A.; Li, F.; Leone, G.; Ostrowski, M.C. Pten in the breast tumor microenvironment: Modeling tumor-stroma coevolution. Cancer Res., 2011, 71, 1203-1207.
157. Trimboli, A.J.; Cantemir-Stone, C.Z.; Li, F.; Wallace, J.A.; Merchant, A.; Creasap, N.; Thompson, J.C.; Caserta, E.; Wang, H.; Chong, J.L.; Naidu, S.; Wei, G.; Sharma, S.M.; Stephens, J.A.; Fernandez, S.A.; Gurcan, M.N.; Weinstein, M.B.; Barsky,S.H.; Yee, L.; Rosol, T.J.; Stromberg, P.C.; Robinson, M.L.; Pepin, F.; Hallett, M.; Park.; M, Ostrowski, M.C.; Leone, G. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature, 2009, 461, 1084-1091.
158. Bronisz, A.; Godlewski, J.; Wallace, J.A.; Merchant, A.S.; Nowicki, M.O.; Mathsyaraja, H.; Srinivasan, R.; Trimboli, A.J.; Martin, C.K.; Li, F.; Yu, L.; Fernandez, S.A.; Pot, T.; Rosol, T.J.; Cory, S.; Hallett, M.; Park, M.; Piper, M.G.; Marsh, C.B.; Yee, L.D.; Jimenez, R.E.; Nuovo, G.; Lawler, S.E.; Chiocca, E.A.; Leone, G.; Ostrowski, M.C. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat. Cell Biol., 2011, 14, 159-167.
159. Yuan, T.L.; Cantley, L.C. PI3K pathway alterations in cancer: Variations on a theme. Oncogene, 2008, 27, 5497-5510.
160. Cheng, Z.; Yang, N.; Liang, W.; Yan, X.; Li, L.; Pan, L. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells. Leuk. Lymphoma, 2012, 53, 1383-1389.
161. Steelman, L.S.; Navolanic P.; Chappell W.H.; Abrams S.L.; Wong E.W.; Martelli A.M.; Cocco L.; Stivala F.; Libra M.; Nicoletti F.; Drobot L.B.; Franklin R.A., McCubrey J.A. Involvement of Akt and mTOR in chemotherapeutic-and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle, 2011, 10, 3003-3015.
162. Clark, A.S.; West, K.; Streicher, S.; Dennis, P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther., 2002, 1, 707-717.
163. Jin, W.; Wu, L.; Liang, K.; Liu, B.; Lu, Y.; Fan, Z. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br. J. Cancer, 2003, 89, 185-191. (Pubitemid 36897956)
164. Hafsi, S.; Pezzino, F.M.; Candido, S.; Ligresti, G.; Spandidos, D.A.; Soua, Z.; McCubrey, J.A.; Travali, S.; Libra, M. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drugresistance. Int. J. Oncol., 2012, 40, 639-644.
165. Page, C.; Lin, H.J.; Jin, Y.; Castle, V.P.; Nunez, G.; Huang, M.; Lin, J. Overexpression of Akt/AKT can modulate chemotherapyinduced apoptosis. Anticancer Res., 2000, 20, 407-416. (Pubitemid 30189787)
166. Liedtke, C.; Cardone, L.; Tordai, A.; Yan, K.; Gomez, H.L.; Figureoa, L.J.; Hubbard, R.E., Valero, V.; Souchon, E.A., Symmans, W.F.; Hortobagyi, G.N.; Bardelli, A.; Pusztai, L. PIK3CAactivating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res., 2008, 10, R27.
167. Brognard, J.; Clark, A.S.; Ni, Y.; Dennis, P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res., 2001, 61, 3986-3997. (Pubitemid 32720961)
168. Liu, L.Z.; Zhou, X.D.; Qian, G.; Shi, X.; Fang, J.; Jiang, B.H. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res., 2007, 67, 6325-6332. (Pubitemid 47037515)
169. Benedetti, V.; Perego, P.; Beretta, G.L; Corna, E.; Tinelli, S.; Righetti, S.C.; Leone, R.; Apostoli, P.; Lanzi, C.; Zunino, F. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol. Cancer Ther., 2008, 7, 679-687. (Pubitemid 351482150)
170. Zhang, H.Y.; Zhang, P.N.; Sun, H. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 146, 81-86.
171. Peng, D.J.; Wang, J.; Zhou, J.Y.; Wu, G.S. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem. Biophys. Res. Commun., 2010, 394, 600-605.
172. Kolasa, I.K.; Rembiszewska, A.; Felisiak, A.; Ziolkowska-Seta, I., Murawska, M.; Moes, J.; Timorek, A.; Dansonka-Mieszkowska, A.; Kupryjanczyk, J. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol. Ther., 2009, 8, 21-26.
173. Engel, J.B.; Schöhals, T.; Häsler, S.; Krockenberger, M.; Schmidt, M.; Horn, E.; Köster, F.; Dietl, J.; Wischhusen, J.; Honig. A. Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. Arch. Gynecol. Obstet., 2011, 283, 603-610.
174. Hahne, J.C.; Honig, A.; Meyer, S.R.; Gambaryan, S.; Walter, U.; Wischhusen, J.; Hässler, S.F.; Segerer, S.E.; Fujita, N.; Dietl, J.; Engel, J.B. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. Oncol. Rep., 2012, 28, 2023-2028.
175. Bezler, M.; Hengstler, J.G.; Ullrich, A. Inhibition of doxorubicininduced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol. Oncol., 2012, 6, 516-529.
176. Fujiwara, M.; Izuishi, K.; Sano, T.; Hossain, M.A.; Kimura, S.; Masaki, T.; Suzuki, Y. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J. Exp. Clin. Cancer Res., 2008, 27, 76-84.
177. Shi, Y.; Liu, X.; Han, E.K.; Guan, R.; Shoemaker, A.R.; Oleksijew, A.; Woods, K.W.; Fisher, J.P.; Klinghofer, V.; Lasko, L.; McGonigal, T.; Li, Q.; Rosenberg, S.H.; Giranda, V.L.; Luo, Y. Optimal classes of chemotherapeutic agents sensitized by specific small molecule inhibitors of Akt in vitro and in vivo. Neoplasia, 2005, 7, 992-1000.
178. Mondesire, W.H.; Jian, W.; Zhang, H.; Ensor, J.; Hung, M.C.; Mills, G.B.; Meric-Bernstam, F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res., 2004, 10, 7031-7042. (Pubitemid 39383055)
179. Fletcher, J.I.; Haber, M.; Henderson, M.J.; Norris, M.D. ABC transporters in cancer: More than just drug efflux pumps. Nat. Rev. Cancer, 2010, 10, 147-156.
180. Lee, S.W.; Cho, H.Y.; Na, G.; Yoo, M.R., Seo, S.K.; Hur, D.Y.; Han, J.; Lee, C.K., Choi, I. CD40 stimulation induces vincristine resistance via AKT activation and MRP1 expression in a human multiple myeloma cell line. Immunol. Lett., 2012, 144, 41-48.
181. Hegedus, C.; Truta-Feles, K.; Antalffy, G.; Brozik, A.; Kasza, I.; Nemet, K.; Orban, T.I.; ?zvegy-Laczka, C.; Varadi, A.; Sarkadi, B. PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter. Biochem. Biophys. Res. Commun., 2012, 420, 869-874.
182. Chiarini, F.; Del Sole, M.; Mongiorgi, S.; Gaboardi, G.C.; Cappellini, A.; Mantovani, I.; Follo, M.Y.; McCubrey, J.A.; Martelli, A.M. The novel Akt inhibitor, perifosine, induces caspasedependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNKdependent mechanism. Leukemia, 2008, 22, 1106-1116. (Pubitemid 351833776)
183. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: The complexity of targeted inhibitor. Nat. Rev. Cancer, 2005, 5, 341-354. (Pubitemid 40637826)
184. Gajria, D.; Chandarlapaty, S. HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert. Rev. Anticancer Ther., 2011, 11, 263-275.
185. Spector, N.L.; Blackwell, K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol., 2009, 27, 5838-5847.
186. Mohd Sharial, M.S.; Crown, J.; Hennessy, B.T. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann. Oncol., 2012, 23, 3007-16.
187. Burgess, A.W.; Cho, H.S.; Eigenbrot, C.; Ferguson, K.M.; Garrett, T.P.; Leahy, D.J.; Lemmon, M.A.; Sliwkowski M.X.; Ward, C.W.; Yokoyama, S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell., 2003, 12, 541-552. (Pubitemid 37222478)
188. Citri, A.; Yarden, Y. EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell. Biol., 2006, 7, 505-516. (Pubitemid 44036456)
189. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol., 2003, 21, 2787-2799. (Pubitemid 46606324)
190. Adamo, V.; Franchina, T.; Adamo, B.; Denaro, N.; Gambadauro, P.; Chiofalo, G.; Scimone, A.; Caristi, N.; Russo, A.; Giordano, A. Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives. Cancer Biol. Ther., 2009, 8, 206-212.
191. Giaccone, G.; Wang, Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat. Rev., 2011, 37, 456-464.
192. Janmaat, M.L.; Kruyt, F.A.; Rodriguez, J.A.; Giaccone, G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res., 2003, 9, 2316-2326. (Pubitemid 36687658)
193. Cappuzzo, F.; Magrini, E.; Ceresoli, G.L.; Bartolini, S.; Rossi, E.; Ludovini, V.; Gregorc, V.; Ligorio, C.; Cancellieri, A.; Damiani, S.; Spreafico, A.; Paties, C.T.; Lombardo, L.; Calandri, C.; Bellezza. G.; Tonato, M.; Crino L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-lung cancer. J. Natl. Cancer. Inst., 2004, 96, 1133-1141. (Pubitemid 39207049)
194. Cappuzzo, F.; Ligorio, C.;. Janne, P.A.; Toschi, L.;Rossi, E.; Trisolini, R.; Paioli, D.; Holmes, A.J.; Magrini, E.;Finocchiaro, G.; Bartolini, S.; Cancellieri, A.; Ciardiello, F.; Patelli, M.; Crino, L.; Varella-Garcia, M. Prospective study of Gefitinib in Epidermal Growth Factor Receptor fluorescence in situ hybridizationpositive/phospho-Akt-positive or never smoker patients with advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial. J. Clin. Onc., 2007, 25, 2248-55. (Pubitemid 46954651)
195. Han, S.W.; Kim, T.Y.; Jeon, Y.K.; Hwang, P.G.; Im, S.A.; Lee, K.H.; Kim, J.H.; Kim, D.W.; Heo, D.S.; Kim, N.K.; Chung, D.H.; Bang, Y.J. Optimization of patient selection for gefitinib in nonsmall cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation and Akt phosphorylation. Clin. Cancer. Res., 2006, 12, 2538-2544.
196. Sos, M.L.; Koker, M.; Weir, B.A.; Heynck, S.; Rabinovsky, R.; Zander, T.; Seeger, J.M.; Weiss, J.; Fischer, F.; Frommolt, P.; Michel, K.; Peifer, M.; Mermel, C.; Girard, L.; Peyton, M.; Gazdar, A.F.; Minna, J.D.; Garraway, L.A.; Kashkar, H.; Pao, W.; Meyerson, M.; Thomas, R.K. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res., 2009, 69, 3256-3261.
197. Donev, I.S.; Wang, W.; Yamada, T.; Li, Q.; Takeuchi, S.; Matsumoto, K.; Yamori, T.; Nishioka, Y.; Sone, S.; Yano, S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin. Cancer Res., 2011, 17, 2260-2269.
198. Sangodkar, J.; Dhawan, N.S.; Melville, H.; Singh, V.J.; Yuan, E.; Rana, H.; Izadmehr, S.; Farrington, C.; Mazhar, S.; Katz, S.; Albano, T.; Arnovitz, P.; Okrent, R.; Ohlmeyer, M.; Galsky, M.; Burstein D.; Zhang, D.; Politi, K.; Difeo, A.; Narla, G. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J. Clin. Invest., 2012, 122, 2637-2651.
199. Kettunen, E.; Anttila, S.; Seppen, J.K.; Karjalainen, A.; Edgren, H., Lindstr, I.; Salovaara, R.; Niss, A.M.; Salo, J.; Mattson, K.; Hollm, J.; Knuutila, S.; Wikman, H. Differentially expressed genes in nonsmall cell lung cancer: Expression profiling of cancerrelated genes in squamous cell lung cancer. Cancer Genet. Cytogenet., 2004, 149, 98-106. (Pubitemid 38293026)
200. Ito, G.; Uchiyama, M.; Kondo, M.; Mori, S.; Usami, N.; Maeda, O.; Kawabe, T.; Hasegawa, Y.; Shimokata, K.; Sekido, Y. Kruppellike factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res., 2004, 64, 3838-3843. (Pubitemid 38697293)
201. Tabara, K.; Kanda, R.; Sonoda, K.; Kubo, T.; Murakami, Y.; Kawahara, A.; Azuma, K.; Abe, H.; Kage, M.; Yoshinaga, A.; Tahira, T.; Hayashi, K.; Arao, T.; Nishio, K.; Rosell, R.; Kuwano, M.; Ono, M. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS One, 2012, 7, e41017.
202. Li, H.; Schmid-Bindert, G.; Wang, D.; Zhao, Y.; Yang, X.; Su, B.; Zhou, C. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines Adv. Med. Sci., 2011, 56, 275-284.
203. Bao, R.; Lai, C.J.; Wang, D.G.; Qu, H.; Yin, L.; Zifcak, B.; Tao, X.; Wang, J.; Atoyan, R.; Samson, M.; Forrester, J.; Xu, G.X.; DellaRocca, S.; Borek, M.; Zhai, H.X.; Cai, X.; Qian, C. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol. Cancer Ther., 2009, 8, 3296-3306.
204. Shimamura, T.; Li, D.; Ji, H.; Haringsma, H.J.; Liniker, E.; Borgman, C.L.; Lowell, A.M.; Minami, Y.; McNamara, K.; Perera, S.A.; Zaghlul, S.; Thomas, R.K.; Greulich, H.; Kobayashi, S.; Chirieac, L.R.; Padera, R.F.; Kubo, S.; Takahashi, M.; Tenen, D.G.; Meyerson, M.; Wong, K.K.; Shapiro, G.I. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res., 2008, 68, 5827-5838.
205. Nielsen, T.O.; Andrews, H.N.; Cheang, M.; Kucab, J.E.; Hsu, F.D.; Ragaz, J.; Gilks, C.B.; Makretsov, N.; Bajdik, C.D.; Brookes, C.; Neckers, L.M.; Evdokimova, V; Huntsman, D.G.; Dunn, S.E. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17-allylamino geldanamycin. Cancer Res., 2004, 64, 286-291. (Pubitemid 38114109)
206. Baselga, J.; Albanell, J.; Ruiz, A.; Lluch, A.; Gascon, P.; Guillem, V.; Gonzaez, S.; Sauleda, S.; Marimon, I.; Tabernero, J.M.; Koehler, M.T.; Rojo, F. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol., 2005, 23, 5323-5333. (Pubitemid 46206986)
207. Lee, C.W.; Simin, K.; Liu, Q.; Plescia, J.; Guha, M.; Khan, A.; Hsieh, C.C.; Altieri, D.C. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res., 2008, 10, R97.
208. Reedijk, M.; Pinnaduwage, D.; Dickson, B.C.; Mulligan, A.M.; Zhang, H., Bull, S.B.; O'Malley, F.P.; Egan, S.E.; Andrulis, I.L. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res. Treat., 2008, 111, 439-448.
209. Dong, Y., Li, A.; Wang, J.; Weber, J.D.; Michel, L.S. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res., 2010, 70, 5465-5474.
210. Suda, K.; Tomizawa, K.; Osada, H.; Maehara, Y., Yatabe, Y.; Sekido, Y.; Mitsudomi, T. Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer, 2012, 76, 292-299.
211. Takata, M.; Chikumi, H.; Miyake, N.; Adachi, K.; Kanamori, Y.; Yamasaki, A.; Igishi, T.; Burioka, N.; Nanba, E.; Shimizu, E. Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity. Cancer Biol. Ther., 2012, 13, 369-378.
212. Lee-Hoeflich, S.T.; Crocker, L.; Yao, E.; Pham, T.; Munroe, X.; Hoeflich, K.P.; Sliwkoski, M.X.; Stern, H.M. A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res., 2008, 68, 5878-5887.
213. Yakes, F.M.; Chinratanalab, W.; Ritter, C.A.; King, W.; Seelig, S.; Arteaga, C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res., 2002, 62, 4132-4141. (Pubitemid 34791085)
214. Grell, P.; Fabian, P.; Khoylou, M.; Radova, L:, Slaby, O.; Hrstka, R.; Vyzula, R.; Hajduch, M.; Svoboda, M. Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Int. J. Oncol., 2012, doi: 10.3892/ijo.2012.1576.
215. Nagata, Y.; Lan, K.H.; Zhou, X.; Tan, M.; Esteva, F.J.; Sahin, A.A.; Klos, K.S.; Li, P.; Monia, B.P.; Nguyen, N.T.; Hortobagyi, G.N.; Hung, M.C.; Yu, D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6, 117-127. (Pubitemid 39485684)
216. Berns, K.; Horlings, H.M.; Hennessy, B.T.; Madiredjo, M.; Hijmans, E.M.; Beelen, K.; Linn, S.C.; Gonzalez-Angulo, A.M.; Stemke-Hale, K.; Hauptmann, M.; Beijersbergen, R.L.; Mills, G.B.; van de Vijver, M.J.; Bernards, R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell, 2007, 12, 395-402. (Pubitemid 47539306)
217. Sakr, R.A.; Barbashina, V.; Morrogh, M.; Chandarlapaty, S.; Andrade, V.P.; Arroyo, C.D.; Olvera, N.; King, T.A. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl. Immunohistochem. Mol. Morphol., 2010, 18, 371-374.
218. Kalinsky, K.;Jacks, L.M.; Heguy, A.; Patil, S.; Drobnjak, M.; Bhanot, U.K.; Hedvat, C.V.; Traina, T.A.; Solit, D.; Gerald, W.;Moynahan, M.E. PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res., 2009, 15, 5049-5059.
219. Scaltriti, M.; Rojo, F.; Ocana, A.; Anido, J.; Guzman, M.; Cortes, J.; Di Cosimo, S.; Matias-Guiu, X.; Ramon, Y.; Cajal, S.; Arribas, J.; Baselga, J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst., 2007, 99, 628-638. (Pubitemid 47073544)
220. Lu, Y.; Zi, X.; Zhao, Y.; Mascarenhas, D.; Pollak, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J. Natl. Cancer Inst., 2001, 93, 1852-1857. (Pubitemid 34048651)
221. Scaltriti, M.; Chandarlapaty, S.; Prudkin, L.; Aura, C.; Jimenez, J.; Angelini, P.D.; Sáchez, G.; Guzman, M.; Parra, J.L.; Ellis, C.; Gagnon, R.; Koehler, M.; Gomez, H.; Geyer, C.; Cameron, D.; Arribas, J.; Rosen, N.; Baselga, J. Clinical benefit of lapatinibbased therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin. Cancer Res., 2010, 16, 2688-2695.
222. Johnston, S.; Trudeau, M.; Kaufman, B.; Boussen, H.; Blackwell, K.; LoRusso, P.; Lombardi, D.P.; Ben Ahmed, S.; Citrin, D.L.; DeSilvio, M.L.; Harris, J.; Westlund, R.E.; Salazar, V.; Zaks, T.Z.; Spector, N.L. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J. Clin. Oncol., 2008, 26, 1066-1072.
223. Rexer, B.N.; Ham, A.J.; Rinehart, C.; Hill, S.; Granja-Ingram Nde M.; Gonzaez-Angulo, A.M.; Mills, G.B.; Dave, B.; Chang, J.C.; Liebler, D.C.; Arteaga, C.L. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene, 2011, 30, 4163-4174.
224. Zardavas, D.; Fumagalli, D.; Loi, S.; Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: A breakthrough in the management of luminal (ER+/HER2-) breast cancers? Curr. Opin. Oncol., 2012, 24, 623-634.
225. Miller, T.W.; Balko, J.M.; Arteaga, C.L. Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer. J. Clin. Oncol., 2011, 29, 4452-4461.
226. Campbell, R.A.; Bhat-Nakshatri, P.; Patel, N.M.; Constantinidou, D.; Ali, S.; Nakshatri, H. Phosphatidylinositol 3-kinase/AKTmediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J. Biol. Chem., 2001, 276, 9817-9824.
227. Sun, M.; Paciga, J.E.; Feldman, R.I.; Yuan, Z.Q.; Ma, X.L.; Shelley, S.A.; Jove, R.; Tsichlis, P.N.; Nicosia, S.V.; Cheng, J.Q. Phosphatidylinositol- 3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res., 2001, 61, 5985-5991. (Pubitemid 32762525)
228. Song, R.X.; Fan, P.; Yue, W.; Chen, Y.; Santen, R.J. Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. Endocr. Relat. Cancer, 2006, 13, S3-13.
229. Goel, V.K.; Lazar, A.J.; Warneke, C.L.; Redston, M.S.; Haluska, F.G. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol., 2006, 126, 154-160. (Pubitemid 43336107)
230. Zhou, X.P.; Gimm, O.; Hampel, H.; Niemann, T.; Walker, M.J.; Eng, C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol., 2000, 157, 1123-1128.
231. Stahl, J.M.; Sharma, A.; Cheung, M.; Zimmerman, M.; Cheng, J.Q.; Bosenberg, M.W.; Kester, M.; Sandirasegarane, L.; Robertson, G.P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res., 2004, 64, 7002-7010. (Pubitemid 39331010)
232. Cheung, M.; Sharma, A.; Madhunapantula, S.V.; Robertson, G.P. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res., 2008, 68, 3429-3439.
233. Inamdar, G.S.; Madhunapantula, S.V.; Robertson, G.P. Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochem. Pharmacol., 2010, 80, 624-637.
234. Chen, B.; Tardell, C.; Higgins, B.; Packman, K.; Boylan, J.F.; Niu, H. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One, 2012, 7, e42598.
235. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9, 28-39.
236. Lindsley, C.W. The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress towards target validation: A 2009 update. Curr. Top Med. Chem., 2010, 10, 458-477.
237. Li, Q.; Zhu, G.D. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr. Top Med. Chem., 2002, 2, 939-971.
238. Barnett, S.F.; Bilodeau, M.T.; Lindsley, C.W. The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress towards target validation. Curr. Top. Med. Chem., 2005, 5, 109-125. (Pubitemid 40514509)
239. Reuveni, H.; Livnah, N.; Geiger, T.; Klein, S.; Ohne, O.; Cohen, I.; Benhar, M.; Gellerman, G.; Levitzki, A. Toward a PKB inhibitor: Modification of a selective PKA inhibitor by rational design. Biochemistry, 2002, 41, 10304-10314. (Pubitemid 34856456)
240. Garcia-Echeverria, C.; Sellers, W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 2008, 27, 5511-5526.
241. Luo, Y.; Shoemaker, A.R.; Liu, X.; Woods, K.W.; Thomas, S.A.; de Jong, R.; Han, E.K.; Li, T.; Stoll, V.S.; Powlas, J.A.; Oleksijew, A.; Mitten, M.J.; Shi, Y.; Guan, R.; McGonigal, T.P.; Klinghofer, V.; Johnson, E.F.; Leverson, J.D.; Bouska, J.J.; Mamo, M., Smith, R.A.; Gramling-Evans, E.E.; Zinker, B.A.; Mika, A.K.; Nguyen, P.T.; Oltersdorf, T.; Rosenberg, S.H.; Li, Q.; Giranda, V.L. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther., 2005, 4, 977-986. (Pubitemid 40909080)
242. Freeman-Cook, K.D.; Autry, C.; Borzillo, G.; Gordon, D.; Barbacci-Tobin, E.; Bernardo, V.; Briere, D.; Clark, T.; Corbett, M.; Jakubczak, J.; Kakar, S.; Knauth, E.; Lippa, B.; Luzzio, M.J.; Mansour, M.; Martinelli, G.; Marx, M.; Nelson, K.; Pandit, J.; Rajamohan, F.; Robinson, S.; Subramanyam, C.; Wei, L.; Wythes, M.; Morris, J. Design of selective, ATP-competitive inhibitors of Akt. J. Med. Chem., 2010, 53, 4615-4622.
243. Zhao, Z.; Leister, W.H.; Robinson, R.G.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Hartman, G.D.; Huff, J.R.; Huber, H.E.; Duggan, M.E.; Lindsley, C.W. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 905-909. (Pubitemid 40458621)
244. Lindsley, C.W.; Zhao, Z.; Leister, W.H.; Robinson, R.G.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Hartman, G.D.; Huff, J.R.; Huber, H.E.; Duggan, M.E. Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 761-764. (Pubitemid 40143162)
245. Zhao, Z.; Robinson, R.G.; Barnett, S.F., Defeo-Jones, D.; Jones, R.E., Hartman, G.D.; Huber, H.E.; Duggana, M.E.; Lindsley, C.W. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg. Med. Chem. Lett., 2008, 18, 49-53.
246. Hirai, H.; Sootome, H.; Nakatsuru, Y.; Miyama, K.; Taguchi, S.; Tsujioka, K.; Ueno, Y.; Hatch, H.; Majumder, P.K.; Pan, B.S.; Kotani, H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther., 2010, 9, 1956-1967.
247. Meuillet, E.J. Novel inhibitors of AKT: Assessment of a different approach targeting the pleckstrin homology domain. Curr. Med. Chem., 2011, 18, 2727-2742.
248. Meuillet, E.J.; Mahadevan, D.; Vankayalapati, H.; Berggren, M.; Williams, R.; Coon, A.; Kozikowski, A.P.; Powis, G. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxyphosphatidyl-myo-inositol analogues. Mol Cancer Ther., 2003, 2, 389-399.
249. Castillo, S.S.; Brognard, J.; Petukhov, P.A.; Zhang, C.; Tsurutani, J.; Granville, C.A.; Li, M.; Jung, M.; West, K.A.; Gills, J.G.; Kozikowski, A.P.; Dennis, P.A. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res., 2004, 64, 2782-2792. (Pubitemid 38500616)
250. Gills, J.J.; Dennis, P.A. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin. Investig. Drugs, 2004, 13, 787-797. (Pubitemid 39028931)
251. Ahad, A.M.; Zuohe, S.; Du-Cuny, L.; Moses, S.A.; Zhou, L.L.; Zhang, S.; Powis, G.; Meuillet, E.J.; Mash, E.A. Development of sulfonamide AKT PH domain inhibitors. Bioorg. Med. Chem., 2011, 19, 2046-2054.
252. Moses, S.A.; Ali, M.A.; Zuohe, S.; Du-Cuny, L.; Zhou, L.L.; Lemos, R.; Ihle, N.; Skillman, A.G.; Zhang, S.; Mash, E.A.; Powis, G.; Meuillet, E.J. In vitro and in vivo activity of novel smallmolecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res., 2009, 69, 5073-5081.
253. Mahadevan, D.; Powis, G.; Mash, E.A.; George, B.; Gokhale, V.M.; Zhang, S.; Shakalya, K.; Du-Cuny, L.; Berggren, M.; Ali, M.A., Jana, U.; Ihle, N.; Moses, S.; Franklin, C.; Narayan, S; Shirahatti, N.; Meuillet, E.J. Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol. Cancer Ther., 2008, 7, 2621-2632.
254. Litman, P.; Ohne, O.; Ben-Yaakov, S.; Shemesh-Darvish, L.; Yechezkel, T.; Salitra, Y.; Rubnov, S., Cohen, I.; Senderowitz, H.; Kidron, D.; Livnah, O.; Levitzki, A.; Livnah, N. A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. Biochemistry, 2007, 46, 4716-4724. (Pubitemid 46651194)
255. Pal, S.K.; Reckamp, K.; Yu, H.; Figlin, R.A. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs, 2010, 19, 1355-1366.
256. Brodeur, G.M. Getting into the AKT. J. Natl.Cancer Inst., 2010, 102, 747-749.
257. Janku, F.; Wheler, J.J.; Naing, A.; Falchook, G.S.; Hong, D.S.; Stepanek, V.M.; Fu, S.; Piha-Paul, S.A.; Lee, J.J.; Luthra, R.; Tsimberidou, A.M.; Kurzrock, R. PIK3CA Mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-Phase Clinical Trials. Cancer Res., 2013, 73, 276-284.
258. Busaidy, N.L.; Farooki, A.; Dowlati, A.; Perentesis, J.P.; Dancey, J.E.; Doyle, L.A.; Brell, J.M.; Siu, L.L. Management of metabolic effects associated with anticancer agents targeting the PI3K-AktmTORpathway. J. Clin. Oncol., 2012, 30, 2919-2928.
259. Restuccia, D.F.; Hemmings, B.A. From man to mouse and back again: Advances in defining tumor AKTivities in vivo. Dis. Model Mech., 2010, 3, 705-20.
260. Carracedo, A.; Ma. L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A.T.; Thomas, G.; Kozma, S.C.; Papa, A.; Nardella, C.; Cantley, L.C.; Baselga, J.; Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human